Baidu
map

口服食物激发试验标准化流程专家共识

2018-08-25 中华预防医学会 中国全科医学杂志.2018.8.

近年来过敏性疾病的发病率逐年升高,其中食物过敏影响了许多婴幼儿、儿童的身心健康和生长发育,以及成年人的生活质量。食物过敏主要是免疫介导包括IgE 介导、细胞介导以及混合介导的慢性疾病,可出现多系统(包括皮肤黏膜、消化系统、呼吸系统等)症状,有时也会出现危及生命的严重过敏反应。食物过敏的诊断取决于详细的临床病史、过敏原皮肤点刺试验(SPT)和过敏原特异性IgE(sIgE)检测及口服食物激发试验。

中文标题:

口服食物激发试验标准化流程专家共识

发布机构:

中华预防医学会

发布日期:

2018-08-25

简要介绍:

近年来过敏性疾病的发病率逐年升高,其中食物过敏影响了许多婴幼儿、儿童的身心健康和生长发育,以及成年人的生活质量。食物过敏主要是免疫介导包括IgE 介导、细胞介导以及混合介导的慢性疾病,可出现多系统(包括皮肤黏膜、消化系统、呼吸系统等)症状,有时也会出现危及生命的严重过敏反应。食物过敏的诊断取决于详细的临床病史、过敏原皮肤点刺试验(SPT)和过敏原特异性IgE(sIgE)检测及口服食物激发试验。 

拓展指南:过敏相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=口服食物激发试验标准化流程专家共识)] GetToolGuiderByIdResponse(projectId=1, id=8a16a1c001633157, title=口服食物激发试验标准化流程专家共识, enTitle=, guiderFrom=中国全科医学杂志.2018.8., authorId=null, author=, summary=近年来过敏性疾病的发病率逐年升高,其中食物过敏影响了许多婴幼儿、儿童的身心健康和生长发育,以及成年人的生活质量。食物过敏主要是免疫介导包括IgE 介导、细胞介导以及混合介导的慢性疾病,可出现多系统(包括皮肤黏膜、消化系统、呼吸系统等)症状,有时也会出现危及生命的严重过敏反应。食物过敏的诊断取决于详细的临床病史、过敏原皮肤点刺试验(SPT)和过敏原特异性IgE(sIgE)检测及口服食物激发试验。 , cover=, journalId=null, articlesId=null, associationId=174, associationName=中华预防医学会, associationIntro=中华预防医学会是全国公共卫生预防医学领域的科技工作者自愿组成并依法在民政部登记注册的非营利性、公益性、学术性法人社团,是全国性学术团体,是发展我国预防医学科学技术和预防医学事业的重要社会力量。, copyright=0, guiderPublishedTime=Sat Aug 25 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>近年来过敏性疾病的发病率逐年升高,其中食物过敏影响了许多婴幼儿、儿童的身心健康和生长发育,以及成年人的生活质量。食物过敏主要是免疫介导包括IgE 介导、细胞介导以及混合介导的慢性疾病,可出现多系统(包括皮肤黏膜、消化系统、呼吸系统等)症状,有时也会出现危及生命的严重过敏反应。食物过敏的诊断取决于详细的临床病史、过敏原皮肤点刺试验(SPT)和过敏原特异性IgE(sIgE)检测及口服食物激发试验。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>过敏</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=76d991c0016102e4" title="中国过敏性鼻炎诊治指南(英文版)" target=_blank>中国过敏性鼻炎诊治指南(英文版)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=1f6081c001605222" title="我国过敏性结膜炎诊断和治疗专家共识(2018年)" target=_blank>我国过敏性结膜炎诊断和治疗专家共识(2018年)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=d3e811c00156e28c" title="奥马珠单抗治疗过敏性哮喘的中国专家共识" target=_blank>奥马珠单抗治疗过敏性哮喘的中国专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=21c3a1c00152257d" title="2017 AAAAI/ACAAI/JCAAI循证指南:季节性过敏性鼻炎的治疗(更新版)" target=_blank>2017 AAAAI/ACAAI/JCAAI循证指南:季节性过敏性鼻炎的治疗(更新版)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=66f651c001a9599c" title="2017 EAACI免疫治疗指南:过敏的预防" target=_blank>2017 EAACI免疫治疗指南:过敏的预防</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E8%BF%87%E6%95%8F" target=_blank>有关过敏更多指南</a></ul>, tagList=[TagDto(tagId=79774, tagName=口服食物激发试验)], categoryList=[CategoryDto(categoryId=35, categoryName=预防医学, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7216, appHits=31, showAppHits=0, pcHits=4308, showPcHits=4017, likes=108, shares=6, comments=3, approvalStatus=1, publishedTime=Wed Aug 29 21:52:45 CST 2018, publishedTimeString=2018-08-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Aug 29 21:52:45 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 14:08:30 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=口服食物激发试验标准化流程专家共识)])
口服食物激发试验标准化流程专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1000239, encodeId=74b810002398f, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db075254759, createdName=147ec6bem31(暂无昵称), createdTime=Fri Jul 16 22:28:37 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949834, encodeId=9ff094983449, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Sat Mar 20 23:47:51 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341707, encodeId=c157341e07f1, content=学习了,谢谢作者分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 30 06:59:11 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2021-07-16 147ec6bem31(暂无昵称)

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1000239, encodeId=74b810002398f, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db075254759, createdName=147ec6bem31(暂无昵称), createdTime=Fri Jul 16 22:28:37 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949834, encodeId=9ff094983449, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Sat Mar 20 23:47:51 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341707, encodeId=c157341e07f1, content=学习了,谢谢作者分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 30 06:59:11 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2021-03-20 ms5000001146316601

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1000239, encodeId=74b810002398f, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db075254759, createdName=147ec6bem31(暂无昵称), createdTime=Fri Jul 16 22:28:37 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949834, encodeId=9ff094983449, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Sat Mar 20 23:47:51 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341707, encodeId=c157341e07f1, content=学习了,谢谢作者分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 30 06:59:11 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

Baidu
map
Baidu
map
Baidu
map